Incyte Corporation announced a leadership transition with Bill Meury appointed as new CEO, succeeding Hervé Hoppenot after 11 years at the helm. Meury brings extensive experience from previous CEO roles at Anthos Therapeutics and Karuna Therapeutics, companies that saw significant acquisition deals. Hoppenot will remain on the board to facilitate a smooth transition. Incyte's strategic shift seeks to diversify beyond its blockbuster Jakafi franchise as patents approach expiration.